New drug AZD4360 targets Hard-to-Treat cancers in early trial

NCT ID NCT06921928

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests a new drug called AZD4360 in adults with advanced solid tumours that have a specific marker (CLDN18.2). The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial aims to find the safest dose and see if it shrinks tumours in people with stomach, gastroesophageal junction, bile duct, or pancreatic cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD4360 (an antibody-drug conjugate targeting CLDN18.2)
What this could lead to: If it works, this could point toward a new treatment option for certain advanced stomach, bile duct, or pancreatic cancers.
What could go wrong: This is an early-phase trial with only 117 participants, so the drug may not prove effective or safe enough for wider use. Side effects could be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BILIARY TRACT CANCER GASTRIC CANCER GASTROESOPHAGEAL JUNCTION CANCER PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Research Site

Santa Monica, California, 90404, United States
Research Site

Providence, Rhode Island, 02903, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Beijing, 100730, China
Research Site

Chengdu, 610041, China
Research Site

Shanghai, 201318, China
Research Site

Wuhan, 430040, China
Research Site

Dresden, 01307, Germany
Research Site

Frankfurt, 60488, Germany
Research Site

Chūōku, 104-0045, Japan
Research Site

Kashiwa, 227-8577, Japan
Research Site

Kōtoku, 135-8550, Japan
Research Site

Glasgow, G12 0YN, United Kingdom
Research Site

London, EC1A 7BE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.